ATE294865T1 - Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance' - Google Patents

Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance'

Info

Publication number
ATE294865T1
ATE294865T1 AT99904857T AT99904857T ATE294865T1 AT E294865 T1 ATE294865 T1 AT E294865T1 AT 99904857 T AT99904857 T AT 99904857T AT 99904857 T AT99904857 T AT 99904857T AT E294865 T1 ATE294865 T1 AT E294865T1
Authority
AT
Austria
Prior art keywords
staphylokinase
dna fragment
derivatives
identification
reduced
Prior art date
Application number
AT99904857T
Other languages
English (en)
Inventor
Desire Jose Collen
Original Assignee
Thromb X N V
Desire Jose Collen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thromb X N V, Desire Jose Collen filed Critical Thromb X N V
Application granted granted Critical
Publication of ATE294865T1 publication Critical patent/ATE294865T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99904857T 1998-02-04 1999-02-04 Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance' ATE294865T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98200323 1998-02-04
EP98200365 1998-02-06
PCT/EP1999/000748 WO1999040198A2 (en) 1998-02-04 1999-02-04 Identification, production and use of staphylokinase derivatives with reduced immunogenicity and/or reduced clearance

Publications (1)

Publication Number Publication Date
ATE294865T1 true ATE294865T1 (de) 2005-05-15

Family

ID=26150019

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99904857T ATE294865T1 (de) 1998-02-04 1999-02-04 Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance'

Country Status (9)

Country Link
US (1) US20050136045A1 (de)
EP (1) EP1053330B1 (de)
JP (1) JP2002505082A (de)
CN (1) CN1322126C (de)
AT (1) ATE294865T1 (de)
AU (1) AU2521999A (de)
CA (1) CA2319693A1 (de)
DE (1) DE69925110T2 (de)
WO (1) WO1999040198A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60028248T2 (de) * 1999-12-02 2007-03-15 Thromb-X N.V. Verfahren zur Reduzierung der Immunogenität von Staphylokinase durch Entfernen von T-Zell-Epitopen
CN100342007C (zh) * 2000-01-28 2007-10-10 复旦大学 一种新型重组葡激酶及其制备方法
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
WO2003007889A2 (en) 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN100445389C (zh) * 2005-10-14 2008-12-24 中国人民解放军军事医学科学院基础医学研究所 一种低抗原性重组葡激酶突变体及制备方法
CN100445390C (zh) * 2005-10-14 2008-12-24 中国人民解放军军事医学科学院基础医学研究所 一种高活性、低抗原性葡激酶衍生体及制备方法
CN101112358B (zh) * 2006-07-26 2011-04-20 中国科学院上海生命科学研究院 葡激酶肌肉注射剂及其制备方法
WO2009046742A1 (en) * 2007-10-09 2009-04-16 Thrombogenics N.V. Staphylokinase variant
RU2422153C1 (ru) * 2010-03-26 2011-06-27 Эспосито Трейдинг Лтд РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК, СОДЕРЖАЩАЯ ПОСЛЕДОВАТЕЛЬНОСТЬ ЗРЕЛОЙ СТАФИЛОКИНАЗЫ STAPHYLOCOCCUS AUREUS С ЗАМЕНАМИ КОДОНОВ K74, E75 И R77 НА ТРИПЛЕТЫ, КОДИРУЮЩИЕ Ala, ШТАММ ESCHERICHIA COLI MZ09 И СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО БЕЛКА, СОДЕРЖАЩЕГО ПОСЛЕДОВАТЕЛЬНОСТЬ ГЕНА ЗРЕЛОЙ СТАФИЛОКИНАЗЫ С ЗАМЕНАМИ КОДОНОВ K74, E75 И R77 НА ТРИПЛЕТЫ, КОДИРУЮЩИЕ Ala
CN102451471B (zh) * 2010-10-14 2013-10-16 中国科学院过程工程研究所 聚乙二醇-葡激酶偶联物及其制备方法和应用
CN102212512B (zh) * 2011-04-22 2015-10-21 河北师范大学 一种聚乙二醇化的葡激酶突变体及其制备方法和应用
CN104293762A (zh) * 2014-09-30 2015-01-21 河北师范大学 聚乙二醇-葡激酶突变体偶联物的制备及纯化方法
US10597453B2 (en) 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147989T1 (de) * 1991-06-28 1997-02-15 Leuven Res & Dev Vzw Verwendung von staphylokinase für die herstellung einer zusammensetzung für die behandlung von gefässthrombose
HU218043B (hu) * 1991-12-30 2000-05-28 Thromb-X N.V., Eljárás szignálpeptid-mentes sztafilokinázok expressziójára
EP0721982A1 (de) * 1995-01-06 1996-07-17 Leuven Research & Development V.Z.W. Neue staphylokinase Derivative

Also Published As

Publication number Publication date
US20050136045A1 (en) 2005-06-23
WO1999040198A3 (en) 1999-09-30
DE69925110D1 (de) 2005-06-09
CA2319693A1 (en) 1999-08-12
EP1053330A2 (de) 2000-11-22
EP1053330B1 (de) 2005-05-04
CN1322126C (zh) 2007-06-20
WO1999040198A2 (en) 1999-08-12
AU2521999A (en) 1999-08-23
CN1293712A (zh) 2001-05-02
DE69925110T2 (de) 2006-02-02
JP2002505082A (ja) 2002-02-19

Similar Documents

Publication Publication Date Title
DE69925110D1 (de) Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance'
CY1116110T1 (el) ΔΙΑΛΥΤΗ ΓΛΥΚΟΠΡΩΤΕΪΝΗ ΥΑΛΟΥΡΟΝΙΔΑΣΗΣ (sHASEGP), ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΗΣ, ΧΡΗΣΕΙΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΛΑΜΒΑΝΟΥΝ
DE60134003D1 (de) Verfahren und zusammensetzungen zur vermeidung und behandlung von anämie
DE69433820D1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
IL86693A0 (en) Novel proteins with factor viii activity,process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
BE2014C077I2 (de)
AU1796788A (en) Blood substitutes
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
BR9910023A (pt) Conjugados de poliol-ifn-beta
NO960111D0 (no) Preparater og metoder for stimulering av vekst og differensiering av megakaryocytter
HU9202435D0 (en) Blood factors produced by a recombinant process, method for expressing said bloode factors and recombinant vaccina viruses utilized in said method
MX2022007546A (es) Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.
MY104910A (en) New derivatives of human/bovine4 basic fibroblast growth factor.
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
HUT40695A (en) Dna sequences, recombinant dna molecules and processes for preparing humane lipocortine like polypeptides
PL375087A1 (en) Low molecular weight oversulfated polysaccharide
ATE139568T1 (de) Achromobacter-protease-i-gen sowie genprodukt
ATE140389T1 (de) Hämoglobin-oligomer basierte komposition und seine herstellung
ATE85893T1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
DK0542869T3 (da) Vævsplasminogenaktivatorvarianter med nedsat udskillelse
DK161738C (da) Fremgangsmaade til indblanding af et laegemiddel i et rygeligt tobaksprodukt
EP1126858A4 (de) Herstellung eines biologischen faktors und schaffung einer immunologisch vorteilhaften umgebung unter verwendung genetisch veränderter sertolizellen
Stegnar et al. Progressive exposure of E-neoantigen associated with degradation of crosslinked fibrin by plasmin in vitro
DE04000874T1 (de) Menschliches therapeutisches Albumin mit niedriger Aluminiumbindungsfähigkeit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties